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96 Session: Disease & Treatmentvital to maintain the balance of bone homeostasis. Our early article elucidated
myricitrin could protect from osteoporotic bone mass reduction via reducing reac-
tive oxygen species (ROS) in osteoblastic bone formation; however, the influence
of osteoclastogenesis by myricitrin is still unclear. Here, we exhibited that myrici-
trin could decrease the TRAP positive cell number significantly in a dose-depen-
dent manner during osteoclast maturation, but it had no effect to pre-osteoclast
proliferation. Consistently, osteoclast maturation markers, and the bone resorp-
tive pits number and area were decreased. Taken together, myricitrin could inhibit
osteoclastogenesis.
http://dx.doi.org/10.1016/j.jot.2016.06.087297
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Background: Telomere length plays a vital role in genomic stability and shortened
telomeres may cause genomic instability and carcinogenesis. Mitochondria exert a
potential role in energy metabolism, free radical production, apoptosis, and may
be involved in cancer progression. Both telomere length and alteration of mito-
chondrial DNA (mtDNA) copy number have been proposed as biomarkers for several
cancers. Nevertheless, few studies have examined the association of telomere
length and mtDNA copy number in musculoskeletal tumours. This study aimed to
examine telomere length and mtDNA copy number in peripheral blood leukocytes,
neoplastic tissues, and non-neoplastic adjacent tissues of patients with musculo-
skeletal tumours. The second objective of this study was to investigate the rela-
tionship of telomere length and mtDNA copy number in musculoskeletal tumours.
Subjects and Methods: Peripheral blood leukocytes (nZ41), neoplastic tissues
(nZ46), and non-neoplastic adjacent tissues (nZ32) were obtained from patients
with musculoskeletal tumours. Relative telomere length and relative mtDNA copy
number were evaluated by quantitative real-time polymerase chain reaction.
Results: Relative telomere length in neoplastic tissues was significantly shorter than
that in non- neoplastic adjacent tissues (p Z 0.001). Shorter relative telomere
length in neoplastic tissues compared to non-neoplastic tissues was observed in
female and male (pZ 0.018 and pZ 0.019, respectively). In addition, the relative
telomere length in malignant tissues was significantly decreased as compared with
that in adjacent non-neoplastic tissues (p Z 0.016). While the relative telomere
length in malignant tissues seemed to be lower than that in benign tissues, there
was no significant difference. The relative telomere length in peripheral blood
leukocytes was not correlated with that in neoplastic tissues. In contrast, relative
mtDNA copy number in neoplastic tissues was not different when compared to
that in non-neoplastic adjacent tissues. The relative mtDNA copy number in periph-
eral blood leukocytes was not associated with that in neoplastic tissues. Interest-
ingly, relative mtDNA copy number in neoplastic tissues was significantly higher
than that in peripheral blood leukocytes (p < 0.001). Further analysis showed that
there was a negative association between relative telomere length and mtDNA
copy number in patients with musculoskeletal tumours (rZ -0.306; pZ 0.104).
Discussion and Conclusion: Relative telomere length in neoplastic tissues was
significantly shorter than that in non-neoplastic adjacent tissues, suggesting that
neoplastic tissues (especially malignant tissues) may undergo several cell divisions
which could lead to progressively shorter telomeres. This finding demonstrated
that relative mtDNA copy number in tissues was significantly higher than that in pe-
ripheral blood leukocytes. The explanation of this finding could be due to speci-
ficity of mtDNA copy number in different types of tissues. The relative telomere
length is inversely associated with the relative mtDNA copy number, indicating
that telomere length attrition and mtDNA alteration are necessary events in
musculoskeletal tumour progression.
http://dx.doi.org/10.1016/j.jot.2016.06.088340
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Background: Primary and metastatic cancers that affect bone are frequently asso-
ciated with severe and intractable pain. Bone cancer pain has been reported with
unique mechanisms and is resistant to morphine treatment. Previous studies have
indicated that change of m-opioid receptor (MOR) expression may be involved in
the pathogenesis of bone cancer pain. In addition, neuron-restrictive silencerfactor (NRSF) has been recently reported to modulate transcription of the MOR
gene. The present study elucidates the regulatory mechanisms of MOR and its po-
tential to effect bone cancer pain.
Methods: Using a sarcoma inoculated murine model, pain behaviours that repre-
sent continuous or breakthrough pain were evaluated. Immunofluorescent staining
was used to check the expression of NRSF in the dorsal root ganglion (DRG).
Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot anal-
ysis were used to quantify expression of NRSF at the transcriptional and transla-
tional levels, respectively. Additionally, chromatin immunoprecipitation assays
were used to detect NRSF binding to the promoter of MOR. Furthermore, NRSF
was genetically knocked out by antisense oligodeoxynucleotide (AS-ODN), and
the expression of MOR and the effect of morphine were subsequently analysed.
Results: Our results indicated that in a sarcoma murine model, expression of NRSF
is upregulated in the DRG neurons and the expression of NRSF mRNA is significantly
negatively correlated with expression of MOR mRNA. Additionally, chromatin
immunoprecipitation analysis revealed that NRSF binding to the neuron-restrictive
silencer element within the promoter area of the MOR gene is significantly pro-
moted with a hypo-acetylation state of histone H3. Furthermore, genetically
knocking down of NRSF with AS-ODN rescued the expression of MOR, with potenti-
ation of system morphine analgesia.
Discussion and Conclusion: The present results suggest that in sarcoma induced
bone cancer pain, NRSF induced downregulation of MOR is involved in the reduction
of morphine analgesia. Epigenetically, up-regulation of MOR could substantially
improve the effect of system delivery of morphine. The results indicate that NRSF
plays an important role in the modulation of MOR transcription and may represent
a novel analgesic target for bone cancer pain. What should be noted is that the
expression of opioid receptors are not only regulated at the transcriptional level,
but are also controlled by extensive post-transcriptional processing. Further studies
are needed at both the preclinical and clinical levels to develop pharmacological
therapy and to effectively block/relieve bone cancer pain with the goal of
increasing the functional status and quality of life of humans with bone cancer pain.
http://dx.doi.org/10.1016/j.jot.2016.06.089367
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Introduction: MicroRNAs (miRNAs) play important roles in the regulation of target
gene expression to coordinate a broad spectrum of biological processes. There is
increasing evidence that multiple miRNAs serve as important regulators of osteoblast
differentiation and bone formation. Significantly, recent studies have discovered that
miR-214, miR-103a, and miR-103, were sensitive to mechanical stimulation to regu-
late osteoblast differentiation or proliferation. However, functional roles of miRNAs
in mechano-transduction in bone formation and further mechanisms in vivo and in vi-
tro have not been well-characterised and, therefore, particularly remain to be eluci-
dated. This study aimed to identify specific miRNAs and their regulatory roles in the
process of bone loss induced by mechanical unloading condition.
SubjectsandMethods:Bonespecimensfrom70osteoporotic individualswithbedridden
states were collected. Twenty-one-month mice and HLU mice were used as the osteo-
porosis model. The RPM machine as an unloading model was used to culture cells.
Results: We assessed the expression of miRNAs involved in bone formation in bone
specimens from 70 osteoporotic individuals with bedridden states in clinical set-
tings. The expression of miR-138-5p altered with bedridden time and was nega-
tively correlated with the expression of the bone formation marker genes ALP in
bedridden women and men. Moreover, consistent results were found in bone tissue
and ALP positive cells in hind limb unloading (HLU) and 20-month aging mice. In
addition, we found that high miR-138-5p expression increased gradually and ALP
activity decreased in osteoblasts after RPM treatment for 12, 24, 48 hours. Target
prediction analysis tools and luciferase activity were used to confirm microtubule
actin crosslinking factor 1 (MACF1) as a direct target of miR-138-5p, and miR-138-
5p inhibited MACF1 expression and osteoblast differentiation in vitro. We treated
mouse preosteoblast MC3T3-E1 cells with antagomir-138-5p and cultured cells un-
der RPM condition. The results indicated that miR-138-5p functions as a mechani-
cal unloading sensitive miRNA and plays a negative role in RPM-induced osteoblast
differentiation reduction. Predominantly, we found an inhibitory role of miR-138-
5p in regulating the bone formation in HLU mice and in vivo pre-treatment with
antagomir-138-5p partly recovered the bone loss caused by hind limb unloading.
Discussion and Conclusion: Taken together, these results suggest that in vivo in-
hibition of miR-138-5p by antimiR-138-5p could represent a potential therapeutic
strategy for ameliorating bone loss.
Funding/support: This work was supported by the National Natural Science Foun-
dation of China (31400725, 31570940).
Session: Disease & Treatment 97References
[1] Yasir Arfat, AiRong Qian, et al. Role of microRNAs in osteoblasts differentiation
and bone disorders. Current Medicinal Chemistry. 2015;22(6):748-58.
http://dx.doi.org/10.1016/j.jot.2016.06.090385
MACF1 POSITIVELY REGULATES OSTEOBLAST DIFFERENTIATION VIA b-
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Introduction: Microtubule-actin crosslinking factor 1 (MACF1) is a key cytoskeletal
linker and plays a critical role in numerous cells [1]. We have previously demon-
strated MACF1 to be highly expressed in osteoblastic cells and participated in
the osteoblasts response to environmental stimuli [2]. However, the role of
MACF1 in osteoblast function is not well understood. Studies show that MACF1 is
critical for embryo development by activating Wnt/b-catenin signalling, which
also plays a key role in regulating osteoblast differentiation. We therefore aimed
to investigate whether MACF1 regulates osteoblast differentiation through Wnt/b-
catenin signalling in this study.
Subjects and Methods: Stable MACF1-knockdown MC3T3-E1 preosteoblasts con-
structed by lentivirus-mediated short-hairpin RNA (shRNA) targeting MACF1 gene
were adopted. The MC3T3-E1 preosteoblasts infected by control-shRNA were
used as a control. Alizarin red s staining was applied to detect mineralised nodules
formation. Real time PCR was used to detect the mRNA expression of alkaline
phosphatase (ALP), runt-related transcription factor 2 (Runx2), and T-cell factor
1 (TCF1). The luciferase reporter assay was further used to detect the TCF1 tran-
scriptional activity. Moreover, the b-catenin and GSK-3b levels were measured by
western blot with and without lithium chloride treatment.
Results: MACF1-knockdown (MACF1-KD) significantly inhibited mineralised nodules
formation and osteogenic gene expression. The translocation of b-catenin into the
nucleus was decreased by MACF1-knockdown and the downstream TCF1 transcrip-
tional activity and Runx2 expression were significantly suppressed. However, 6
hour treatment of 30mMLiCl inhibitedGSK-3b activation, induced b-catenin nuclear
translocation and partly restored the decreased expression of TCF1 and Runx2.
These findings showed that MACF1 deficiency inhibited osteoblast differentiation
and the nuclear translocation of b-catenin, suggesting that MACF1 positively regu-
lates osteoblast differentiation and may act through GSK3b/b-catenin signalling.
Discussion and Conclusion: The present study uncovers, for the first time an
important role of MACF1 in osteoblasts and suggests that MACF1 may positively
regulate osteoblast differentiation via b-catenin/TCF1-Runx2 signalling and acts
upstream of GSK-3b/b-catenin signalling.
Funding/support: This work was supported by the National Natural Science Foun-
dation of China (31400725, 31570940), the Project Funded by China Postdoctoral
Science Foundation (2015T81051), and the Project Supported by Natural Science
Basic Research Plan in Shaanxi Province of China (2015JM3078,2015JQ3076).
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Background and objective: Osteosarcoma is the most common primary malig-
nancy of bone. Abnormal expression and activation of the receptor tyrosine ki-
nases (RTKs) play a vital role in the occurrence and development of
osteosarcoma. Studies show that c-Kit, a type III RTK, which is activated by itsligand, stem cell factor (SCF), and the newly-identified signalling mediator Gai
were both over-expressed in human OS tissues and cell line. The two also formed
a signalling complex. Further studies showed that c-Kit-Gai recruited the adaptor
protein Gab1 (Grb2-associated binder 1) to transduce downstream signalling. This
study was designed from a perspective of signalling pathway to investigate the role
of c-Kit-Gai complex in the proliferation of osteosarcoma.
Methods: The expression of Gai1/3, c-kit, and Gab1 of OS cell lines (U2OS, MG-63),
osteoblasts (MC3TC-E1), and bone cells (OB-6) were detected by western blot.
MG63 cells were incubated with 0, 0.1, 1, 5, 25, and 50ng/ml of SCF for 24 and
48 hours. The cell proliferation was detected by Brdu method and the cell survival
was detected by MTT. The MG63 cells were cultured with 50ng/ml SCF for 0, 5, 10,
20, and 30 minutes, western blot was used to detect the expression of T- Kit, P-Kit,
T-Gab1, P-Gab1, T-AKT, Akt473, P-S6K, P-PLC, T-PLC, T-S6, P-S6, T-ERK, and P-
ERK. We used the shRNA-mediated silencing or genetic knockout of Gai in the
MG-63 cells, and further detection of the activation conditions of Akt-mTOR and
Erk-MAPK downstream signalling (T-AKT, Akt473, Akt308, GSK3a/3b, mTOR, S6K,
S6, ERK) in the cells induced by SCF.
Results: The expression of c-Kit, Gai1/3, and Gab1 in cultured OS cell lines (U2OS,
MG-63) was significantly higher than those of osteoblasts (MC3TC-E1) and bone
cells (OB-6). In MG-63 cells, the exogenous SCF increased the phosphorylation of
c-Kit, Gab1, Akt473, S6K, PLC, S6, and ERK, activated signalling pathways, and
then promoted cell proliferation and survival. shRNA-mediated silencing or genetic
knockout of Gai dramatically inhibited the phosphorylation of Akt473, Akt308,
GSK3a/3b, mTOR, S6K, S6, and ERK, which was activated by SCF.
Conclusion: The c-Kit-Gai complex transduces Akt-mTOR and Erk-MAPK down-
stream signalling activated by SCF, and then plays a key role in maintaining and
promoting the survival and proliferation of osteosarcoma cells. The target therapy
aimed at the complex will provide a new approach to curb and treat osteosarcoma.
Funding/support: This study was sponsored by a grant from the National Natural
Science Foundation of China (no. 81171712), Jiangsu Province’s Key Provincial Tal-
ents Program (2011e15), and Jiangsu Province’s Key Medical Department in 2011.
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Introduction: Osteosarcoma (OS) is the most frequent primary bone sarcoma,
which is generally regarded as a differentiation disease that is caused by genetic
and epigenetic disruptions of terminal differentiation of osteoblasts. Bone
morphogenetic protein 9(BMP9) is probably the most osteogenic differentiation
potent inducer, but whether it can induce osteogenic differentiation of OS is un-
clear. All-trans retinoic acid (ATRA) can restore normal osteogenesis in OS. In
this study, we aim to identify the relationship between ATRA and BMP9 in inducing
osteogenesis differentiation of OS.
Subjects and Methods: 143B, OS cell line, were used to explore the mechanisms of
regulating differentiation and proliferation during treatment with ATRA and (or)
BMP9. The level of protein expression was tested by western blot assay. The levels
of mRNA expression were tested by Semi-quantitative RT-PCR (sqPCR). ALP activity
was assessed by a modified Great Escape SEAP Chemiluminescence assay. The pro-
liferation effects were tested by crystal violet staining.
Results: In 143B cells, BMP9 could not up-regulate the expression of osteogenesis
markers (such as Runx-2, Dlx-5, ALP, OPN, and OCN) but conversely, it could promote
proliferationof cells. Then,we found thatATRA successfully enhanced thesemarkers,
and it significantly inhibited proliferation of cells. The expression levels of BMP9were
up-regulated after ATRA treatment. Cells stimulated by treating with ATRA and BMP9
exhibited higher expression levels of osteogenesismarkers, than that treated byATRA
or BMP9, and also the effect of anti-proliferation of ATRA was enhanced. During dif-
ferentiation induction, the expression level of P-p38 was up-regulated with ATRA
treatment, which was higher than that with ATRA or BMP9 treatment. The osteogen-
esis markers induced by ATRA or ATRA and BMP9, were down-regulated by treated
with SB (p38 inhibitor SB203580). Meanwhile, SB could promote the proliferation of
143B cells; it also reversed the anti-proliferation of ATRA.
Discussion and Conclusion: According to the results of all above, we find that BMP9
fails to induce osteogenic differentiation of 143B cells alone, which is inconsistent
with the previous report that BMP2 can promote differentiation of OS, indicating
the existence of possible differentiation of BMP9 defects in OS. We found that ATRA
successfully induces osteoblastic differentiation of osteosarcoma cells in vitro and
it significantly inhibited proliferation of 143B cells, which is consistent with other re-
ports. Meanwhile, ATRA up-regulated the expression levels of BMP9 inOS. The expres-
sion levels of osteogenic-related genes were enhanced when BMP9 combined with
ATRA. Thus, we suppose that in the osteogenic potential restoration of BMP9 in OS,
ATRAmay play a critical role. During differentiation induction, the p38MAPK pathway
mayhavean important role in the control of osteogenesis-related genes expression. In
conclusion, this studydemonstrates thatATRAcanrestore theosteogeniccapabilityof
